SLC5A2 and chronic kidney disease: The latest recommendations from the KDIGO indicate that the use of renin–angiotensin system inhibitors and sodium–glucose co-transporter-2 inhibitors (SGLT2 inhibitors) offers significant benefits for patients with CKD.